October 05, 2017

Not intended for U.S. and UK Media

Bayer's NAVIGATE ESUS study halted early as it indicated comparable efficacy between treatment arms

Phase III NAVIGATE ESUS study evaluated rivaroxaban vs aspirin in patients with embolic stroke of undetermined source (ESUS) / The study at interim indicates no efficacy improvement over low dose aspirin and very little chance of showing overall benefit if the study were completed / The positive benefit risk profile of rivaroxaban remains unchanged in all licensed indications
Berlin, October 5, 2017 - Bayer AG and its development partner Janssen Research
& Development, LLC today announced that the Phase III NAVIGATE ESUS study
evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the secondary
prevention of stroke and systemic embolism in patients with a recent embolic
stroke of undetermined source (ESUS) has been stopped early. Based on the
recommendation by the Independent Data Monitoring Committee (IDMC) following a
planned interim analysis, the trial was halted early as it showed comparable
efficacy between the rivaroxaban and aspirin arms and very little chance of
showing overall benefit if the study were completed. While bleeding rates were
low overall, an increase in bleeding was observed in the rivaroxaban arm
compared to the low dose aspirin arm. The decision to halt the trial was taken
jointly by the Academic Leadership of the trial and the sponsor Bayer.

ESUS refers to patients with embolic stroke documented by neuroimaging for
which the cause remains unidentified despite thorough investigations attempting
to rule out established cardiac and vascular sources. It does not include
patients with atrial fibrillation or established atherosclerotic disease and
therefore the patient population in NAVIGATE ESUS differs from the currently
approved indications for rivaroxaban. Despite recommended treatments, the
stroke recurrence risk for patients with ESUS remains substantial.

"Patients with ESUS currently have limited treatment options and the role of
anticoagulants in this area remains uncertain. We will now analyze the data
from NAVIGATE ESUS to better understand this outcome and its implications,"
said Dr Joerg Moeller, Member of the Executive Committee of Bayer AG's
Pharmaceutical Division and Head of Development. "Patients will be contacted by
their physician to switch to standard of care, aspirin. Patients should not
stop trial medication without consultation of their physicians. We are
committed to continuing the extensive investigation of rivaroxaban for patients
at risk of deadly blood clots."

The Phase III NAVIGATE ESUS (1) study has enrolled 7,214 patients from 459
sites across 31 countries worldwide. In the study, patients were randomized to
receive either rivaroxaban 15 mg once daily or aspirin 100 mg once daily alone.
The primary efficacy endpoint was a composite of stroke (ischemic, hemorrhagic
and undefined stroke, transient ischemic attack with positive neuroimaging) and
systemic embolism. The primary safety endpoint was major bleeding according to
the criteria of the International Society on Thrombosis and Haemostasis (ISTH).
A complete data analysis is expected to be presented at an upcoming medical
meeting in 2018.

About Xarelto® (Rivaroxaban)

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral
anticoagulant (NOAC) and is marketed under the brand name Xarelto®. Xarelto is
approved for seven indications, protecting patients across more venous and
arterial thromboembolic (VAT) conditions than any other NOAC:

- The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) and one or more risk factors

- The treatment of pulmonary embolism (PE) in adults

- The treatment of deep vein thrombosis (DVT) in adults

- The prevention of recurrent PE and DVT in adults

- The prevention of venous thromboembolism (VTE) in adult patients undergoing
elective hip replacement surgery

- The prevention of VTE in adult patients undergoing elective knee replacement
surgery

- The prevention of atherothrombotic events (cardiovascular death, myocardial
infarction or stroke) after an Acute Coronary Syndrome in adult patients with
elevated cardiac biomarkers and no prior stroke or transient ischaemic attack
(TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 130 countries.

Rivaroxaban was discovered by Bayer, and is being jointly developed with
Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by
Bayer and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen Research &
Development, LLC and Janssen Pharmaceuticals, Inc. are part of the Janssen
Pharmaceutical Companies of Johnson & Johnson).

Anticoagulant medicines are potent therapies used to prevent or treat serious
illnesses and potentially life-threatening conditions. Before initiating
therapy with anticoagulant medicines, physicians should carefully assess the
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card for
patients to support best practice.

To learn more about thrombosis, please visit www.thrombosisadviser.com
To learn more about Xarelto, please visit www.xarelto.com

(1) New Approach riVaroxaban Inhibition of factor Xa in a Global trial vs ASA
to prevenT Embolism in Embolic Stroke of Undetermined Source

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 115,200 people and had sales of EUR 46.8 billion. Capital
expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion.
These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October
6, 2015. For more information, go to www.bayer.com

Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/BayerPharma

Find more information at www.bayerpharma.com

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.